| Q35965634 | A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q89052840 | Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study |
| Q34122946 | Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. |
| Q34267385 | Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder |
| Q33886093 | Long-acting risperidone: a review of its role in the treatment of bipolar disorder |
| Q42252223 | Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection |
| Q34349641 | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis |
| Q37803220 | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder |
| Q37062563 | Risperidone long-acting injection: a review of its long term safety and efficacy |